Although rare, severe and life-threatening skin reactions and hepatotoxicity liver damage including fatal cases of each, have occurred. For HIV-positive adults beginning anti-HIV drug therapy for the first time, Viramune is listed as an alternative NNRTI option by the United States Department of Health and Human Services DHHS in its treatment guidelines. Researchers are now testing the safety and effectiveness of this option it has not yet recommended by any experts and has not yet been evaluated by the. After the initial 18 week period, frequent clinical and laboratory monitoring should continue throughout VIRAMUNE treatment. Patient Counseling Information See FDA-Approved Medication Guide The Medication Guide provides written information for the patient, and should be dispensed with each new prescription and refill. Read the Medication Guide provided with this medication for more details. rezept viramune Some experts recommend clinical and laboratory monitoring more often than once per month, and in particular, would include monitoring of liver enzyme tests at baseline, prior to dose escalation and at two weeks post-dose escalation.